新聞Quotient Sciences Limited partnered with Ipsen on Feb 26th '26.Philadelphia, PA - 26 February 2026 - Quotient Sciences, a leading integrated CRDMO (Contract Research, Development and Manufacturing Organization), is pleased to announce an extended commercial supply partnership with Ipsen, a global biopharmaceutical company, to manufacture a treatment for Fibrodysplasia Ossificans Progressiva (FOP), an ultra-rare disease affecting fewer than 1,000 people worldwide.
新聞Origami Therapeutics, Inc. partnered with Ipsen on Jan 30th '26.SAN DIEGO - (BUSINESS WIRE) - Origami Therapeutics, a biotech company developing small molecule protein degraders and conformation correctors to treat neurodegenerative diseases, today announced a global collaboration and option agreement with Ipsen (Euronext: IPN; ADR: IPSEY) to develop a small-molecule protein degrader program targeting a rare, inherited neurodegenerative disorder.
新聞Ipsen attends event EASL Congress 2025.GENFIT: positive late-breaking Phase 2 data for elafibranor in Primary Sclerosing Cholangitis (PSC) to be presented by Ipsen at EASL Congress 2025.
